Hypertrophic cardiomyopathy can be a debilitating condition that currently has no approved therapies to treat it, highlighting the impact of potential treatments like mavacamten, said Jay Edelberg, MD, PhD, senior vice president of Clinical Development at MyoKardia.
Hypertrophic cardiomyopathy can be a debilitating condition that currently has no approved therapies to treat it, highlighting the impact of potential treatments like mavacamten, said Jay Edelberg, MD, PhD, senior vice president of Clinical Development at MyoKardia.
Transcript
What are the clinical and cost burdens of hypertrophic cardiomyopathy on the U.S. health system? Is the burden from this condition increasing?
Hypertrophic cardiomyopathy is a fairly common form of cardiomyopathy—it affects 1 in 500 people in the United States and globally. Hypertrophic cardiomyopathy manifests in a variety of ways for patients. Some people are able to get by with minimal symptoms through a large part of their life. For others, they’re impacted by heart failure, atrial fibrillation, ventricular fibrillation, sudden cardiac death, worsening heart failure–so, it really actually presents in a variety of ways. For some people, they’re just limited by activities of daily living. For others, it actually can really be quite debilitating, and their only options end up being surgery or even heart transplantation.
With the recent JAMA Cardiology study showing an increase in heart failure in the US population, where does mavacamten fit into the treatment paradigm?
Mavacamten is being developed for obstructive hypertrophic cardiomyopathy—we’re in phase 3 in that study. So, this is a sub-form of heart failure–so it’s patients with heart failure that’s due to actually the heart actually working in overtime. It’d be like basically your bicep muscles having to work 24 hours a day, 7 days a week every day of your life. They just become so very big, thick, and frankly so non-compliant that actually they don’t end up working very well–the heart is not able to fill well with blood and it ends up actually leading to a heart failure for those patients there. So, it’s a very specialized form of heart failure. We think that the molecular mechanisms of hypertrophic cardiomyopathy may actually give us insight how to treat some patients with heart failure with preserved ejection fraction. It makes up approximately half of all of heart failure in the US, and we presently don’t have any therapies that are approved for that.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More